Christopher M. Yengo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Christopher M. Yengo has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Jinghua Ge
Department of Cell and Biological Systems, Penn State College of Medicine, Hershey, PA, USA
10 shared publications - Wanjian Tang
Department of Biological Chemistry, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
8 shared publications William C. Unrath
Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, Hershey, PA 17033
8 shared publications- David V. Rasicci
Department of Pathology, Anatomy, and Laboratory Medicine, West Virginia University School of Medicine, Morgantown, USA
7 shared publications - Roger Craig
Division of Cell Biology and Imaging, Department of Radiology, University of Massachusetts Chan Medical School; Worcester, MA, USA
7 shared publications - Skylar M. L. Bodt
Department of Cell and Biological Systems, Penn State College of Medicine, Hershey, PA 17033
7 shared publications
Latest Publications
- Open Access
Disease-associated amino acid substitutions outside canonical motor motifs impair Myo1e localization and activity
Steroid-resistant nephrotic syndrome (SRNS) is a severe kidney disorder characterized by proteinuria and disruption of glomerular filtration, often driven by genetic defects in genes encoding proteins required for podocyte functions. Among these, MYO1E , encoding the actin- and membrane-associated motor protein Myosin 1e (Myo1e), has been implicated in familial and sporadic forms of SRNS. Here, we investigated two MYO1E missense variants, A92E and G562R, identified in trans in a patient with childhood-onset SRNS and located outside canonical P-loop and switch subdomains of the Myo1e motor domain. Both residues are highly conserved, located within predicted α-helices in the motor domain, and replaced by larger charged residues, which may reduce protein stability or folding. In podocyte-derived cells, both mutants failed to localize at intercellular junctions and displayed reduced colocalization with actin. The G562R variant additionally formed cytoplasmic aggregates that were partially expression-level-dependent and exhibited decreased fluorescence recovery after photobleaching, indicating impaired protein dynamics. In vitro motility and ATPase assays indicated that the G562R mutant exhibited a marked loss of ATPase activity while the A92E mutant displayed ATPase activity similar to the WT but was characterized by reduced motility and thermal stability. Together, these results demonstrate that A92E and G562R mutations compromise Myo1e localization and function, supporting their pathogenic role in SRNS.
Open AccessDisease-associated amino acid substitutions outside canonical motor motifs impair Myo1e localization and activity
Steroid-resistant nephrotic syndrome (SRNS) is a severe kidney disorder characterized by proteinuria and disruption of glomerular filtration, often driven by genetic defects in genes encoding proteins required for podocyte functions. Among these, MYO1E , encoding the actin- and membrane-associated motor protein Myosin 1e (Myo1e), has been implicated in familial and sporadic forms of SRNS. Here, we investigated two MYO1E missense variants, A92E and G562R, identified in trans in a patient with childhood-onset SRNS and located outside canonical P-loop and switch subdomains of the Myo1e motor domain. Both residues are highly conserved, located within predicted α-helices in the motor domain, and replaced by larger charged residues, which may reduce protein stability or folding. In podocyte-derived cells, both mutants failed to localize at intercellular junctions and displayed reduced colocalization with actin. The G562R variant additionally formed cytoplasmic aggregates that were partially expression-level-dependent and exhibited decreased fluorescence recovery after photobleaching, indicating impaired protein dynamics. In vitro motility and ATPase assays indicated that the G562R mutant exhibited a marked loss of ATPase activity while the A92E mutant displayed ATPase activity similar to the WT but was characterized by reduced motility and thermal stability. Together, these results demonstrate that A92E and G562R mutations compromise Myo1e localization and function, supporting their pathogenic role in SRNS.
- Open Access
The dilated cardiomyopathy E525K mutation stabilizes the cardiac myosin interacting-heads motif while activating the isolated motor domain
Mutations in β-cardiac myosin are a common cause of inherited cardiomyopathies. The dilated cardiomyopathy E525K mutation alters both thick filament regulation and motor activity, yet the structural basis for these effects has remained unclear. Here, we combined cryo-EM and MD simulations to determine how E525K affects the conformational landscape of cardiac myosin in both its autoinhibited interacting-heads motif (IHM) and isolated myosin head states. E525K-mutated myosin exclusively adopted a single S2 conformation in IHM, in contrast to the conformational heterogeneity observed in wild-type myosin. Structural and electrostatic analyses revealed that the mutation increased positive charge density at the blocked-head (BH) – S2 (subfragment-2) interface, strengthening interactions with negatively charged residues within S2. 3D variability analysis and MD simulations of the E525K IHM demonstrated reduced S2 mobility, consistent with strengthened BH – S2 interactions, and decreased conformational flexibility, providing a structural mechanism for stabilization of the IHM state. To investigate the isolated myosin head, we determined cryo-EM structures of wild-type and E525K subfragment-1 (S1). The mutation induced local conformational rearrangements in the activation-loop and Loop 3 region, the SH3-like domain, and the essential light chain of S1, revealing structural changes that support the enhanced motor activity previously reported for isolated E525K myosin motors. These findings show that E525K stabilizes the autoinhibited IHM through electrostatic stabilization of the BH – S2 interface while inducing structural changes consistent with activation of the isolated motor domain, providing structural insights into how a single DCM mutation differentially regulates cardiac myosin S1 and IHM structure and function.
Open AccessThe dilated cardiomyopathy E525K mutation stabilizes the cardiac myosin interacting-heads motif while activating the isolated motor domain
Mutations in β-cardiac myosin are a common cause of inherited cardiomyopathies. The dilated cardiomyopathy E525K mutation alters both thick filament regulation and motor activity, yet the structural basis for these effects has remained unclear. Here, we combined cryo-EM and MD simulations to determine how E525K affects the conformational landscape of cardiac myosin in both its autoinhibited interacting-heads motif (IHM) and isolated myosin head states. E525K-mutated myosin exclusively adopted a single S2 conformation in IHM, in contrast to the conformational heterogeneity observed in wild-type myosin. Structural and electrostatic analyses revealed that the mutation increased positive charge density at the blocked-head (BH) – S2 (subfragment-2) interface, strengthening interactions with negatively charged residues within S2. 3D variability analysis and MD simulations of the E525K IHM demonstrated reduced S2 mobility, consistent with strengthened BH – S2 interactions, and decreased conformational flexibility, providing a structural mechanism for stabilization of the IHM state. To investigate the isolated myosin head, we determined cryo-EM structures of wild-type and E525K subfragment-1 (S1). The mutation induced local conformational rearrangements in the activation-loop and Loop 3 region, the SH3-like domain, and the essential light chain of S1, revealing structural changes that support the enhanced motor activity previously reported for isolated E525K myosin motors. These findings show that E525K stabilizes the autoinhibited IHM through electrostatic stabilization of the BH – S2 interface while inducing structural changes consistent with activation of the isolated motor domain, providing structural insights into how a single DCM mutation differentially regulates cardiac myosin S1 and IHM structure and function.
- Open Access
- 6 May 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (6) , 113114
Impact of salt concentration and free magnesium on human beta-cardiac myosin reveal important details about the conserved mechanochemical mechanism
- 6 May 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (6) , 113114
Open AccessImpact of salt concentration and free magnesium on human beta-cardiac myosin reveal important details about the conserved mechanochemical mechanism
- Open Access
- 1 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (18) , eaed6472
Cryo-EM reveals how cardiomyopathy therapeutic drugs modulate the myosin motors of the heart
Genetic mutations in myosin, the motor protein that powers the heartbeat, are linked to inherited hypertrophic and dilated cardiomyopathies. Mavacamten and omecamtiv mecarbil are therapeutic, myosin-targeted drugs designed to treat these myopathies, but their mechanism of action has remained unclear. Using single-particle cryo-EM, we determined near-atomic resolution structures of wild-type, mavacamten-bound, and omecamtiv mecarbil–bound myosin molecules. Across all conditions, we observe two distinct, alternate conformations of myosin, not previously reported. We show how mavacamten stabilizes one conformation by reinforcing key electrostatic interfaces in the molecule, whereas omecamtiv mecarbil weakens these interfaces, favoring the second structure. This remodeling elucidates previously unclear allosteric mechanisms through which these drugs either inhibit or enhance myosin activity, countering the deleterious impacts of disease. These findings reveal how drugs modulate myosin structure to control cardiac contractility.
- 1 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (18) , eaed6472
Open AccessCryo-EM reveals how cardiomyopathy therapeutic drugs modulate the myosin motors of the heart
Genetic mutations in myosin, the motor protein that powers the heartbeat, are linked to inherited hypertrophic and dilated cardiomyopathies. Mavacamten and omecamtiv mecarbil are therapeutic, myosin-targeted drugs designed to treat these myopathies, but their mechanism of action has remained unclear. Using single-particle cryo-EM, we determined near-atomic resolution structures of wild-type, mavacamten-bound, and omecamtiv mecarbil–bound myosin molecules. Across all conditions, we observe two distinct, alternate conformations of myosin, not previously reported. We show how mavacamten stabilizes one conformation by reinforcing key electrostatic interfaces in the molecule, whereas omecamtiv mecarbil weakens these interfaces, favoring the second structure. This remodeling elucidates previously unclear allosteric mechanisms through which these drugs either inhibit or enhance myosin activity, countering the deleterious impacts of disease. These findings reveal how drugs modulate myosin structure to control cardiac contractility.
- Open Access
- 21 February 2026
- Published by Elsevier in Journal of Structural Biology
- Vol. 218 (2) , 108299
“QuickStainer”: a rapid negative staining device for improved preservation of molecular structure
- 21 February 2026
- Published by Elsevier in Journal of Structural Biology
- Vol. 218 (2) , 108299
Open Access“QuickStainer”: a rapid negative staining device for improved preservation of molecular structure
- Open Access
Cryo-EM Reveals How Cardiomyopathy Therapeutic Drugs Modulate the Myosin Motors of the Heart
Genetic mutations in myosin, the motor protein that powers the heartbeat, are linked to inherited hypertrophic and dilated cardiomyopathies. Mavacamten and omecamtiv mecarbil are therapeutic, myosin-targeted drugs designed to treat these myopathies, but their mechanism of action has remained unclear. Using single-particle cryo-EM, we determined near-atomic resolution structures of wild-type, mavacamten-bound, and omecamtiv mecarbil-bound myosin molecules. Across all conditions, two conformations of myosin were observed. We show how mavacamten stabilizes one conformation by reinforcing key electrostatic interfaces in the molecule, whereas omecamtiv mecarbil weakens these interfaces, favoring the second structure. This remodeling elucidates previously unclear allosteric mechanisms through which these drugs either inhibit or enhance myosin activity, countering the deleterious impacts of disease. These findings reveal how drugs modulate myosin structure to control cardiac contractility.
Open AccessCryo-EM Reveals How Cardiomyopathy Therapeutic Drugs Modulate the Myosin Motors of the Heart
Genetic mutations in myosin, the motor protein that powers the heartbeat, are linked to inherited hypertrophic and dilated cardiomyopathies. Mavacamten and omecamtiv mecarbil are therapeutic, myosin-targeted drugs designed to treat these myopathies, but their mechanism of action has remained unclear. Using single-particle cryo-EM, we determined near-atomic resolution structures of wild-type, mavacamten-bound, and omecamtiv mecarbil-bound myosin molecules. Across all conditions, two conformations of myosin were observed. We show how mavacamten stabilizes one conformation by reinforcing key electrostatic interfaces in the molecule, whereas omecamtiv mecarbil weakens these interfaces, favoring the second structure. This remodeling elucidates previously unclear allosteric mechanisms through which these drugs either inhibit or enhance myosin activity, countering the deleterious impacts of disease. These findings reveal how drugs modulate myosin structure to control cardiac contractility.
- Open Access
“QuickStainer”: a rapid negative staining device for improved preservation of molecular structure
Negative staining is a widely used technique for observing macromolecules and their assemblies by transmission electron microscopy. It is commonly employed to optimize specimens for cryo-EM. The stain, typically a uranyl salt, surrounds the structure, providing an outline view at about 20 Å resolution. Many macromolecules are relatively stable and rigid, and negative stain images provide a good representation of their structure. However, some are labile or flexible and their structure or assembly state is altered by binding to the carbon substrate on the grid before specimen staining. In these cases, the negatively stained appearance does not faithfully represent the structure in solution. This problem is reduced when samples are incubated on the carbon surface for short times (5 s) rather than typical times (30-60 s) before staining. To reduce disruption to a minimum, we have developed a rapid negative staining device (QuickStainer) using 3D-printed components, a stepper motor for precisely timed movements, and an Arduino-controlled interface to execute commands. QuickStainer produces consistent, reproducible results, achieving sample incubation times as low as 10 ms before staining. Tests show rapid adherence of molecules to the grid and greatly improved structural preservation of labile specimens compared with standard preparation protocols. The design of QuickStainer can accommodate inclusion of additional steps, such as timed incubation with enzyme substrate, before staining.
Open Access“QuickStainer”: a rapid negative staining device for improved preservation of molecular structure
Negative staining is a widely used technique for observing macromolecules and their assemblies by transmission electron microscopy. It is commonly employed to optimize specimens for cryo-EM. The stain, typically a uranyl salt, surrounds the structure, providing an outline view at about 20 Å resolution. Many macromolecules are relatively stable and rigid, and negative stain images provide a good representation of their structure. However, some are labile or flexible and their structure or assembly state is altered by binding to the carbon substrate on the grid before specimen staining. In these cases, the negatively stained appearance does not faithfully represent the structure in solution. This problem is reduced when samples are incubated on the carbon surface for short times (5 s) rather than typical times (30-60 s) before staining. To reduce disruption to a minimum, we have developed a rapid negative staining device (QuickStainer) using 3D-printed components, a stepper motor for precisely timed movements, and an Arduino-controlled interface to execute commands. QuickStainer produces consistent, reproducible results, achieving sample incubation times as low as 10 ms before staining. Tests show rapid adherence of molecules to the grid and greatly improved structural preservation of labile specimens compared with standard preparation protocols. The design of QuickStainer can accommodate inclusion of additional steps, such as timed incubation with enzyme substrate, before staining.
- Open Access
- 15 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6766
Early-Stage Alcoholic Cardiomyopathy Highlighted by Metabolic Remodeling, Oxidative Stress, and Cardiac Myosin Dysfunction in Male Rats
Chronic ethanol use can lead to alcoholic cardiomyopathy (ACM), while the impact on the molecular and cellular aspects of the myocardium is unclear. Accordingly, male Sprague-Dawley rats were exposed to an ethanol-containing diet for 16 weeks and compared with a control group that was fed an isocaloric diet. Histological measurements from H&E slides revealed no significant differences in cell size. A proteomic approach revealed that alcohol exposure leads to enhanced mitochondrial lipid metabolism, and electron microscopy revealed impairments in mitochondrial morphology/density. Cardiac myosin purified from the hearts of ethanol-exposed animals demonstrated a 15% reduction in high-salt ATPase activity, with no significant changes in the in vitro motility and low-salt ATPase or formation of the super-relaxed (SRX) state. A protein carbonyl assay indicated a 20% increase in carbonyl incorporation, suggesting that alcohol may impact cardiac myosin through oxidative stress mechanisms. In vitro oxidation of healthy cardiac myosin revealed a dramatic decline in ATPase activity and in vitro motility, demonstrating a link between myosin protein oxidation and myosin mechanochemistry. Collectively, this study suggests alcohol-induced metabolic remodeling may be the initial insult that eventually leads to defects in the contractile machinery in the myocardium of ACM hearts.
- 15 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6766
Open AccessEarly-Stage Alcoholic Cardiomyopathy Highlighted by Metabolic Remodeling, Oxidative Stress, and Cardiac Myosin Dysfunction in Male Rats
Chronic ethanol use can lead to alcoholic cardiomyopathy (ACM), while the impact on the molecular and cellular aspects of the myocardium is unclear. Accordingly, male Sprague-Dawley rats were exposed to an ethanol-containing diet for 16 weeks and compared with a control group that was fed an isocaloric diet. Histological measurements from H&E slides revealed no significant differences in cell size. A proteomic approach revealed that alcohol exposure leads to enhanced mitochondrial lipid metabolism, and electron microscopy revealed impairments in mitochondrial morphology/density. Cardiac myosin purified from the hearts of ethanol-exposed animals demonstrated a 15% reduction in high-salt ATPase activity, with no significant changes in the in vitro motility and low-salt ATPase or formation of the super-relaxed (SRX) state. A protein carbonyl assay indicated a 20% increase in carbonyl incorporation, suggesting that alcohol may impact cardiac myosin through oxidative stress mechanisms. In vitro oxidation of healthy cardiac myosin revealed a dramatic decline in ATPase activity and in vitro motility, demonstrating a link between myosin protein oxidation and myosin mechanochemistry. Collectively, this study suggests alcohol-induced metabolic remodeling may be the initial insult that eventually leads to defects in the contractile machinery in the myocardium of ACM hearts.
- Open Access
- 16 July 2024
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 3 (8) , pgae279
Dilated cardiomyopathy mutation in beta-cardiac myosin enhances actin activation of the power stroke and phosphate release
Inherited mutations in human beta-cardiac myosin (M2β) can lead to severe forms of heart failure. The E525K mutation in M2β is associated with dilated cardiomyopathy (DCM) and was found to stabilize the interacting heads motif (IHM) and autoinhibited super-relaxed (SRX) state in dimeric heavy meromyosin. However, in monomeric M2β subfragment 1 (S1) we found that E525K enhances (threefold) the maximum steady-state actin-activated ATPase activity (kcat) and decreases (eightfold) the actin concentration at which ATPase is one-half maximal (KATPase). We also found a twofold to fourfold increase in the actin-activated power stroke and phosphate release rate constants at 30 μM actin, which overall enhanced the duty ratio threefold. Loaded motility assays revealed that the enhanced intrinsic motor activity translates to increased ensemble force in M2β S1. Glutamate 525, located near the actin binding region in the so-called activation loop, is highly conserved and predicted to form a salt bridge with another conserved residue (lysine 484) in the relay helix. Enhanced sampling molecular dynamics simulations predict that the charge reversal mutation disrupts the E525-K484 salt bridge, inducing conformations with a more flexible relay helix and a wide phosphate release tunnel. Our results highlight a highly conserved allosteric pathway associated with actin activation of the power stroke and phosphate release and suggest an important feature of the autoinhibited IHM is to prevent this region of myosin from interacting with actin. The ability of the E525K mutation to stabilize the IHM likely overrides the enhanced intrinsic motor properties, which may be key to triggering DCM pathogenesis.
- 16 July 2024
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 3 (8) , pgae279
Open AccessDilated cardiomyopathy mutation in beta-cardiac myosin enhances actin activation of the power stroke and phosphate release
Inherited mutations in human beta-cardiac myosin (M2β) can lead to severe forms of heart failure. The E525K mutation in M2β is associated with dilated cardiomyopathy (DCM) and was found to stabilize the interacting heads motif (IHM) and autoinhibited super-relaxed (SRX) state in dimeric heavy meromyosin. However, in monomeric M2β subfragment 1 (S1) we found that E525K enhances (threefold) the maximum steady-state actin-activated ATPase activity (kcat) and decreases (eightfold) the actin concentration at which ATPase is one-half maximal (KATPase). We also found a twofold to fourfold increase in the actin-activated power stroke and phosphate release rate constants at 30 μM actin, which overall enhanced the duty ratio threefold. Loaded motility assays revealed that the enhanced intrinsic motor activity translates to increased ensemble force in M2β S1. Glutamate 525, located near the actin binding region in the so-called activation loop, is highly conserved and predicted to form a salt bridge with another conserved residue (lysine 484) in the relay helix. Enhanced sampling molecular dynamics simulations predict that the charge reversal mutation disrupts the E525-K484 salt bridge, inducing conformations with a more flexible relay helix and a wide phosphate release tunnel. Our results highlight a highly conserved allosteric pathway associated with actin activation of the power stroke and phosphate release and suggest an important feature of the autoinhibited IHM is to prevent this region of myosin from interacting with actin. The ability of the E525K mutation to stabilize the IHM likely overrides the enhanced intrinsic motor properties, which may be key to triggering DCM pathogenesis.
- Open Access
- 6 May 2024
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 156 (6)
Tail length and E525K dilated cardiomyopathy mutant alter human β-cardiac myosin super-relaxed state
Dilated cardiomyopathy (DCM) is a condition characterized by impaired cardiac function, due to myocardial hypo-contractility, and is associated with point mutations in β-cardiac myosin, the molecular motor that powers cardiac contraction. Myocardial function can be modulated through sequestration of myosin motors into an auto-inhibited “super-relaxed” state (SRX), which may be further stabilized by a structural state known as the “interacting heads motif” (IHM). Here, we sought to determine whether hypo-contractility of DCM myocardium results from reduced function of individual myosin molecules or from decreased myosin availability to interact with actin due to increased IHM/SRX stabilization. We used an established DCM myosin mutation, E525K, and characterized the biochemical and mechanical activity of wild-type and mutant human β-cardiac myosin constructs that differed in the length of their coiled-coil tail, which dictates their ability to form the IHM/SRX state. We found that short-tailed myosin constructs exhibited low IHM/SRX content, elevated actin-activated ATPase activity, and fast velocities in unloaded motility assays. Conversely, longer-tailed constructs exhibited higher IHM/SRX content and reduced actomyosin ATPase and velocity. Our modeling suggests that reduced velocities may be attributed to IHM/SRX-dependent sequestration of myosin heads. Interestingly, longer-tailed E525K mutants showed no apparent impact on velocity or actomyosin ATPase at low ionic strength but stabilized IHM/SRX state at higher ionic strength. Therefore, the hypo-contractility observed in DCM may be attributable to reduced myosin head availability caused by enhanced IHM/SRX stability in E525K mutants.
- 6 May 2024
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 156 (6)
Open AccessTail length and E525K dilated cardiomyopathy mutant alter human β-cardiac myosin super-relaxed state
Dilated cardiomyopathy (DCM) is a condition characterized by impaired cardiac function, due to myocardial hypo-contractility, and is associated with point mutations in β-cardiac myosin, the molecular motor that powers cardiac contraction. Myocardial function can be modulated through sequestration of myosin motors into an auto-inhibited “super-relaxed” state (SRX), which may be further stabilized by a structural state known as the “interacting heads motif” (IHM). Here, we sought to determine whether hypo-contractility of DCM myocardium results from reduced function of individual myosin molecules or from decreased myosin availability to interact with actin due to increased IHM/SRX stabilization. We used an established DCM myosin mutation, E525K, and characterized the biochemical and mechanical activity of wild-type and mutant human β-cardiac myosin constructs that differed in the length of their coiled-coil tail, which dictates their ability to form the IHM/SRX state. We found that short-tailed myosin constructs exhibited low IHM/SRX content, elevated actin-activated ATPase activity, and fast velocities in unloaded motility assays. Conversely, longer-tailed constructs exhibited higher IHM/SRX content and reduced actomyosin ATPase and velocity. Our modeling suggests that reduced velocities may be attributed to IHM/SRX-dependent sequestration of myosin heads. Interestingly, longer-tailed E525K mutants showed no apparent impact on velocity or actomyosin ATPase at low ionic strength but stabilized IHM/SRX state at higher ionic strength. Therefore, the hypo-contractility observed in DCM may be attributable to reduced myosin head availability caused by enhanced IHM/SRX stability in E525K mutants.